Table 2.
Baseline characteristics of adenomatous polyp cohort in training and validation group
|
Variables
|
Total (n = 596)
|
Training group (n = 432)
|
Validation group (n = 164)
|
χ
2/t/Z
|
P value
|
| Male, n (%) | 324 (54.4) | 90 (54.9) | 234 (54.2) | 0.024 | 0.876 |
| Age (year), mean ± SD | 53.02 ± 11.14 | 53.04 ± 11.24 | 52.96 ± 10.91 | 0.089 | 0.929 |
| BMI (kg/m²), mean ± SD | 25.66 ± 3.94 | 25.78 ± 3.94 | 25.31 ± 3.93 | 1.323 | 0.186 |
| Alcohol, n (%) | 179 (30.0) | 127 (29.4) | 52 (31.7) | 0.302 | 0.583 |
| Smoking, n (%) | 193 (32.4) | 145 (33.6) | 48 (29.3) | 1.002 | 0.317 |
| Diabetes, n (%) | 154 (25.8) | 120 (27.8) | 34 (20.7) | 3.080 | 0.079 |
| Hypertension, n (%) | 165 (27.7) | 120 (27.8) | 45 (27.4) | 0.007 | 0.934 |
| MS, n (%) | 96 (16.1) | 69 (16.0) | 27 (16.5) | 0.021 | 0.884 |
| Cirrhosis, n (%) | 285 (47.8) | 215 (49.8) | 70 (42.7) | 2.392 | 0.122 |
| FPG (mmo/L), mean ± SD | 6.15 ± 2.07 | 6.23 ± 2.16 | 5.93 ± 1.85 | -1.573 | 0.116 |
| HDL (mmo/L), mean ± SD | 1.33 ± 0.40 | 1.33 ± 0.41 | 1.33 ± 0.38 | 0.105 | 0.916 |
| CHO (mmo/L), median (IQR) | 4.54 (3.82, 5.38) | 4.57 (3.81, 5.40) | 4.41 (3.85, 5.41) | -0.714 | 0.458 |
| TG (mmo/L), mean ± SD | 1.42 ± 1.12 | 1.44 ± 1.22 | 1.35 ± 0.82 | -0.826 | 0.409 |
| LDL (mmo/L), mean ± SD | 2.81 ± 0.90 | 2.75 ± 0.82 | 2.83 ± 0.93 | -0.979 | 0.382 |
| TP (g/L), mean ± SD | 71.54 ± 7.98 | 71.29 ± 7.76 | 72.19 ± 8.51 | 1.239 | 0.216 |
| ALB (g/L), mean ± SD | 40.75 ± 6.14 | 40.83 ± 6.07 | 40.52 ± 6.34 | -0.551 | 0.582 |
| SI (μmol/L), mean ± SD | 22.36 ± 10.67 | 22.37 ± 10.15 | 22.33 ± 11.97 | -0.040 | 0.968 |
| SF (ug/L), median (IQR) | 165.00 (70.25, 303.25) | 163.00 (76.00, 304.00) | 174.00 (54.50, 295.00) | -0.721 | 0.471 |
| TRF (g/L), mean ± SD | 2.75 ± 0.89 | 2.75 ± 0.91 | 2.76 ± 0.83 | 0.203 | 0.840 |
| TSH (mIU/L), median (IQR) | 1.85 (1.33, 2.83) | 1.94 (1.30, 2.89) | 1.72 (1.34, 2.66) | -1.435 | 0.151 |
| FT4 (pmol/L), mean ± SD | 17.10 ± 14.18 | 17.31 ± 9.77 | 16.57 ± 9.62 | -0.698 | 0.485 |
| FT3 (pmol/L), mean ± SD | 4.98 ± 1.00 | 5.01 ± 1.02 | 4.90 ± 0.94 | -1.245 | 0.214 |
| ALT (IU/L), median (IQR) | 33.20 (19.40, 78.57) | 32.20 (19.10, 76.57) | 34.75 (19.65, 79.25) | -0.610 | 0.542 |
| AST (IU/L), median (IQR) | 33.75 (22.35, 72.47) | 33.75 (22.02, 65.60) | 34.10 (22.62, 78.75) | -0.491 | 0.624 |
| GGT (IU/L), median (IQR) | 53.85 (24.35, 116.77) | 54.55 (24.97, 100.57) | 50.05 (22.07, 163.45) | -0.274 | 0.708 |
BMI: Body mass index; MS: Metabolic syndrome; FPG: Fasting plasma glucose; HDL: High-density lipoprotein; CHO: Cholesterol; TG: Triacylglycerol; LDL: Low-density lipoprotein; PLT: Platelet count; TP: Total protein; ALB: Albumin; SI: Serum iron; SF: Serum ferritin; TRF: Transferrin; TSH: Thyroid-stimulating hormone; FT3: Free T3; FT4: Free T4; ALT: Alanine aminotransferase; AST: Aspartate transaminase; GGT: Gamma-glutamyl transferase; IQR: Interquartile range.